Afuco™ Anti-Human MAG ADCC Recombinant Antibody, ADCC Enhanced (CAT#: AFC-490CL)

Anti-MAG ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. AFC-490CL is an investigational drug intended to help repair brain injury, appears to be safe for patients with stroke, according to a phase I/II study. The drug is a monoclonal antibody that blocks myelin-associated glycoprotein to promote neurite outgrowth and protect oligodendrocytes. Serious adverse events were reported in 10 of 42 subjects and were distributed evenly among three treatment groups. Local investigators considered three of the serious adverse events to be potentially drug-related. No adverse event was fatal. One patient in the high-dose group had acute renal failure 18 days after stroke onset and a second stroke 38 days after stroke onset. One patient in the moderate-dose group had dysgeusia.